Lung Cancer Breakthrough
FDA Clears U.S. Clinical Trial for MAIA's Lung Cancer Drug Ateganosine in Third-Line Patients
MAIA Biotechnology has received FDA clearance to open U.S. enrollment in the expansion of its Phase 2 THIO-101 trial, testing ateganosine in advanced non-small cell lung cancer (NSCLC) patients who have failed at least two prior treatments. Stock Titan reports the news marks a key step toward a potential Accelerated Approval filing with the FDA.
The cleared Investigational New Drug (IND) update covers improved manufacturing, new suppliers, and updated formulation and storage conditions for the drug. About 50,000 U.S. patients each year reach this late-stage point in their disease — a group with few good options and a typical survival of just five to six months.
Survival Data Triple the Standard of Care
Early results from THIO-101 are striking. Third-line NSCLC patients in the Phase 2 trial reached a median overall survival of 17.8 months, according to Clinical Trials Arena. That is more than triple the standard-of-care benchmark of five to six months. Progression-free survival came in at 5.6 months — more than double the typical 2.5-month benchmark.
The disease control rate in third-line patients hit 77%, according to Targeted Oncology. At the European Lung Cancer Congress in March 2026, MAIA reported that eight patients in the trial had survived beyond two years. CEO Dr. Vlad Vitoc said that data "bodes well for Parts C and D evaluations" of the expanded trial.
How Ateganosine Targets Cancer's 'Immortality' Switch
Ateganosine works by attacking a weakness found in more than 85% of cancer cells. Most tumors rely on an enzyme called telomerase to keep their DNA from breaking down — effectively making cancer cells "immortal." Ateganosine gets incorporated into tumor DNA by telomerase, triggering rapid cell death.
The drug also "primes" the immune system. It makes tumors more sensitive to checkpoint inhibitor drugs like cemiplimab (Libtayo). This two-step, sequential approach is what oncology experts at ASCO 2026 called an innovative way to break cancer's resistance to immunotherapy, according to Stock Titan.
Fast Track Status and Phase 3 Trial Already Underway
The FDA granted ateganosine Fast Track designation in July 2025, speeding up its review process. The first patient was dosed in the pivotal Phase 3 THIO-104 trial on December 24, 2025, according to Stock Titan. MAIA presented a "Trial in Progress" poster for the Phase 3 study at ASCO's Annual Meeting in Chicago on May 31, 2026.
MAIA raised $33 million in April 2026 to fully fund the Phase 3 trial. The company also holds a $2.3 million NIH grant. The trial now runs across 44 sites in six countries. MAIA expects to activate up to five U.S. sites for the THIO-101 expansion in 2026, with a second site opening "in the coming weeks," per Weekly Voice.
Accelerated Approval Path Hinges on Expansion Data
If data from the THIO-101 expansion holds up, MAIA plans to file for FDA Accelerated Approval as early as 2027. That pathway would let the drug reach patients before the Phase 3 trial is fully complete. Interim Phase 3 data is also expected in 2027, according to Stock Titan.
The cautious view is worth noting. Some medical researchers point out that the third-line patient subset studied so far is small — around 22 patients in some data cuts. The 300-patient Phase 3 trial is needed to confirm whether the survival gains hold across a broader population, according to ca.finance.yahoo.com. MAIA's stock rose 4.07% to $1.39 on June 3 following the announcement.
Sentiment
NeutralPublishers
5
Articles
4
Reach
5
